# GLP-1 and Hyperoxia for Organ Protection in Heart Surgery

> **NCT02673931** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Rigshospitalet, Denmark** · enrollment: 1400 (actual)

## Conditions studied

- Coronary Disease
- Shock, Cardiogenic
- Renal Failure
- Stroke
- Brain Injury
- Aortic Valve Disease

## Interventions

- **DRUG:** Byetta (Lilly, Exenatide)
- **DRUG:** Conoxia (AGA, oxygen)
- **DRUG:** 20% Human Albumin

## Key facts

- **NCT ID:** NCT02673931
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 1400 (ACTUAL)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02673931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02673931, "GLP-1 and Hyperoxia for Organ Protection in Heart Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02673931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*